PUS1 May Be a Potential Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718 e1701. doi:10.1053/j.gastro.2018.01.064
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang Y, Li S, et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res. 2018;10:1947–1958. doi:10.2147/CMAR.S167036
   PubMed Web of Science ®Google Scholar
• Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212–220. doi:10.1016/j.cca.2013.08.005
   PubMed Web of Science ®Google Scholar
• Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531–538. doi:10.1158/1055-9965.EPI-18-0281
   PubMed Web of Science ®Google Scholar
• Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7(3):308–319. doi:10.1016/j.gendis.2020.01.014
   PubMed Web of Science ®Google Scholar
• Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–322. doi:10.1038/s41568-020-0253-2
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. doi:10.1186/s12943-019-1109-9
   PubMed Web of Science ®Google Scholar
• Penzo M, Guerrieri AN, Zacchini F, Trere D, Montanaro L. RNA Pseudouridylation in physiology and medicine: for better and for worse. Genes. 2017;8(11):11. doi:10.3390/genes8110301
   Web of Science ®Google Scholar
• De Zoysa MD, Yu YT. Posttranscriptional RNA Pseudouridylation. Enzymes. 2017;41:151–167.
   PubMedGoogle Scholar
• Terns M, Terns R. Noncoding RNAs of the H/ACA family. Cold Spring Harb Symp Quant Biol. 2006;71:395–405. doi:10.1101/sqb.2006.71.034
   PubMedGoogle Scholar
• Balogh E, Chandler JC, Varga M, et al. Pseudouridylation defect due to DKC1 and NOP10 mutations causes nephrotic syndrome with cataracts, hearing impairment, and enterocolitis. Proc Natl Acad Sci U S A. 2020;117(26):15137–15147. doi:10.1073/pnas.2002328117
   PubMed Web of Science ®Google Scholar
• Dos Santos PC, Panero J, Stanganelli C, et al. Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia. PLoS One. 2017;12(6):e0179883. doi:10.1371/journal.pone.0179883
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim SS, Yoo NJ, Lee SH. Expressional analysis of NOLA1, NOLA2, NOLA3 and DKC1, the core proteins in H/ACA riboproteins, in gastric and colorectal cancers. Pathology. 2012;44(6):576–577. doi:10.1097/PAT.0b013e3283583bf6
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao W, Liu S, et al. H/ACA snoRNP gene family as diagnostic and prognostic biomarkers for hepatocellular carcinoma. Pharmgenomics Pers Med. 2021;14:1331–1345. doi:10.2147/PGPM.S333838
   PubMed Web of Science ®Google Scholar
• Rintala-Dempsey AC, Kothe U. Eukaryotic stand-alone pseudouridine synthases - RNA modifying enzymes and emerging regulators of gene expression? RNA Biol. 2017;14(9):1185–1196. doi:10.1080/15476286.2016.1276150
   PubMed Web of Science ®Google Scholar
• Bykhovskaya Y, Casas K, Mengesha E, Inbal A, Fischel-Ghodsian N. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet. 2004;74(6):1303–1308. doi:10.1086/421530
   PubMed Web of Science ®Google Scholar
• de Brouwer APM, Abou Jamra R, Kortel N, et al. Variants in PUS7 cause intellectual disability with speech delay, microcephaly, short stature, and aggressive behavior. Am J Hum Genet. 2018;103(6):1045–1052. doi:10.1016/j.ajhg.2018.10.026
   PubMed Web of Science ®Google Scholar
• Jana S, Hsieh AC, Gupta R. Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis. Cell Death Dis. 2017;8(10):e3093. doi:10.1038/cddis.2017.476
   PubMed Web of Science ®Google Scholar
• Zhang Q, Fei S, Zhao Y, et al. PUS7 promotes the proliferation of colorectal cancer cells by directly stabilizing SIRT1 to activate the Wnt/beta-catenin pathway. Mol Carcinog. 2023;62(2):160–173. doi:10.1002/mc.23473
   PubMed Web of Science ®Google Scholar
• Du J, Gong A, Zhao X, Wang G. Pseudouridylate synthase 7 promotes cell proliferation and invasion in colon cancer through activating PI3K/AKT/mTOR signaling pathway. Dig Dis Sci. 2022;67(4):1260–1270. doi:10.1007/s10620-021-06936-0
   PubMed Web of Science ®Google Scholar
• Jin Z, Song M, Wang J, et al. Integrative multiomics evaluation reveals the importance of pseudouridine synthases in hepatocellular carcinoma. Front Genet. 2022;13:944681. doi:10.3389/fgene.2022.944681
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48(5):500–509. doi:10.1038/ng.3547
   PubMed Web of Science ®Google Scholar
• Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202–10212. doi:10.1158/0008-5472.CAN-10-2607
   PubMed Web of Science ®Google Scholar
• Lin Z, Xu Q, Miao D, Yu F. An inflammatory response-related gene signature can impact the immune status and predict the prognosis of hepatocellular carcinoma. Front Oncol. 2021;11:644416. doi:10.3389/fonc.2021.644416
   PubMed Web of Science ®Google Scholar
• Mo S, Fang D, Zhao S, et al. Down regulated oncogene KIF2C inhibits growth, invasion, and metastasis of hepatocellular carcinoma through the Ras/MAPK signaling pathway and epithelial-to-mesenchymal transition. Ann Transl Med. 2022;10(3):151. doi:10.21037/atm-21-6240
   PubMed Web of Science ®Google Scholar
• Motorin Y, Keith G, Simon C, et al. The yeast tRNA: pseudouridine synthase Pus1p displays a multisite substrate specificity. RNA. 1998;4(7):856–869. doi:10.1017/S1355838298980396
   PubMed Web of Science ®Google Scholar
• Behm-Ansmant I, Massenet S, Immel F, Patton JR, Motorin Y, Branlant C. A previously unidentified activity of yeast and mouse RNA: pseudouridinesynthases 1 (Pus1p) on tRNAs. RNA. 2006;12(8):1583–1593. doi:10.1261/rna.100806
   PubMed Web of Science ®Google Scholar
• Carlile TM, Rojas-Duran MF, Zinshteyn B, Shin H, Bartoli KM, Gilbert WV. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature. 2014;515(7525):143–146. doi:10.1038/nature13802
   PubMed Web of Science ®Google Scholar
• Martinez NM, Su A, Burns MC, et al. Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing. Mol Cell. 2022;82(3):645–659 e649. doi:10.1016/j.molcel.2021.12.023
   PubMed Web of Science ®Google Scholar
• Zhao X, Patton JR, Davis SL, Florence B, Ames SJ, Spanjaard RA. Regulation of nuclear receptor activity by a pseudouridine synthase through posttranscriptional modification of steroid receptor RNA activator. Mol Cell. 2004;15(4):549–558. doi:10.1016/j.molcel.2004.06.044
   PubMed Web of Science ®Google Scholar
• Komili S, Silver PA. Coupling and coordination in gene expression processes: a systems biology view. Nat Rev Genet. 2008;9(1):38–48. doi:10.1038/nrg2223
   PubMed Web of Science ®Google Scholar
• van Dam S, Vosa U, van der Graaf A, Franke L, de Magalhaes JP. Gene co-expression analysis for functional classification and gene-disease predictions. Brief Bioinform. 2018;19(4):575–592. doi:10.1093/bib/bbw139
   PubMed Web of Science ®Google Scholar
• Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177–197.
   PubMed Web of Science ®Google Scholar
• Boese AC, Kang S. Mitochondrial metabolism-mediated redox regulation in cancer progression. Redox Biol. 2021;42:101870. doi:10.1016/j.redox.2021.101870
   PubMed Web of Science ®Google Scholar
• Kwon SM, Lee YK, Min S, Woo HG, Wang HJ, Yoon G. Mitoribosome defect in hepatocellular carcinoma promotes an aggressive phenotype with suppressed immune reaction. iScience. 2020;23(6):101247. doi:10.1016/j.isci.2020.101247
   PubMed Web of Science ®Google Scholar
• Lee HY, Nga HT, Tian J, Yi HS. Mitochondrial metabolic signatures in hepatocellular carcinoma. Cells. 2021;10:8.
   Web of Science ®Google Scholar
• Tuli HS, Kaur J, Vashishth K, et al. Molecular mechanisms behind ROS regulation in cancer: a balancing act between augmented tumorigenesis and cell apoptosis. Arch Toxicol. 2023;97(1):103–120. doi:10.1007/s00204-022-03421-z
   PubMed Web of Science ®Google Scholar
• Liang JQ, Teoh N, Xu L, et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat Commun. 2018;9(1):4490. doi:10.1038/s41467-018-06931-6
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–121. doi:10.1053/j.gastro.2005.04.014
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. doi:10.1016/S0016-5085(98)70599-2
   PubMed Web of Science ®Google Scholar
• Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–20728. doi:10.3390/ijms141020704
   PubMed Web of Science ®Google Scholar
• Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers. 2020;12(2):491. doi:10.3390/cancers12020491
   PubMed Web of Science ®Google Scholar
• He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21(1):159–168. doi:10.1038/cr.2010.183
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39(1):26–42. doi:10.1055/s-0038-1676806
   PubMed Web of Science ®Google Scholar
• Liu P, Ge M, Hu J, et al. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017;66(1):167–181. doi:10.1002/hep.29183
   PubMed Web of Science ®Google Scholar
• Xin B, Yamamoto M, Fujii K, et al. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways. Oncogene. 2017;36(36):5087–5097. doi:10.1038/onc.2017.114
   PubMed Web of Science ®Google Scholar
• Wang H, Wang P, Xu M, et al. Distinct functions of transforming growth factor-beta signaling in c-MYC driven hepatocellular carcinoma initiation and progression. Cell Death Dis. 2021;12(2):200. doi:10.1038/s41419-021-03488-z
   PubMed Web of Science ®Google Scholar
• Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene. 2013;32(43):5129–5143. doi:10.1038/onc.2012.640
   PubMed Web of Science ®Google Scholar
• Kan G, Wang Z, Sheng C, et al. Dual inhibition of DKC1 and MEK1/2 synergistically restrains the growth of colorectal cancer cells. Adv Sci. 2021;8(10):2004344. doi:10.1002/advs.202004344
   Web of Science ®Google Scholar
• Song D, Guo M, Xu S, et al. HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance. J Exp Clin Cancer Res. 2021;40(1):170. doi:10.1186/s13046-021-01951-5
   PubMed Web of Science ®Google Scholar